BIOMAT Database Logo BIOMAT Database Logo

3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. 1993

M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Department of Medicinal Chemistry, Sterling Winthrop Pharmaceuticals Research Division, Sterling Winthrop Inc., Collegeville, Pennsylvania 19426-0900.

A series of novel 3-quinolinecarboxamides that are structurally similar to the quinolone class of antibacterial agents possess excellent antiherpetic properties. By modifying the quinoline ring at the 1-, 2-, 3-, and 7-positions, analogues were identified that have up to 5-fold increased HSV-2 plaque-reduction potency relative to acyclovir. In a single-dose mouse model of infection, one of the most potent derivatives in vitro, 1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarbo xamide (97), displayed comparable oral antiherpetic efficacy to acyclovir at 1/16 the dose; in a multiple-dose regimen, however, 97 was 2-fold less potent. In mice dosed orally with 97, sustained plasma drug levels were evident that may account for the high efficacy observed. The molecular mechanism of action of these agents is not known; however, based on in vitro studies with acyclovir resistant mutants, it is likely that the mechanism differs from that of acyclovir. In vitro plaque-reduction potency was not generally predictive of oral efficacy in mice. An X-ray crystal structure of 97 corroborated the assignment of structure and provided useful insights as to the effect of conformation on plaque-reduction potency.

UI MeSH Term Description Entries
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010948 Viral Plaque Assay Method for measuring viral infectivity and multiplication in CULTURED CELLS. Clear lysed areas or plaques develop as the VIRAL PARTICLES are released from the infected cells during incubation. With some VIRUSES, the cells are killed by a cytopathic effect; with others, the infected cells are not killed but can be detected by their hemadsorptive ability. Sometimes the plaque cells contain VIRAL ANTIGENS which can be measured by IMMUNOFLUORESCENCE. Bacteriophage Plaque Assay,Assay, Bacteriophage Plaque,Assay, Viral Plaque,Assays, Bacteriophage Plaque,Assays, Viral Plaque,Bacteriophage Plaque Assays,Plaque Assay, Bacteriophage,Plaque Assay, Viral,Plaque Assays, Bacteriophage,Plaque Assays, Viral,Viral Plaque Assays
D011804 Quinolines
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
A novel series of orally active antiplatelet agents.
May 1995, Bioorganic & medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Oxanilic acids, a new series of orally active antiallergic agents.
September 1975, Journal of medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Synthesis of novel 3-carboxamide-benzocoumarin derivatives as orally active antithrombotic agents.
December 2011, Bioorganic & medicinal chemistry letters,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
July 2014, Journal of medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Pyrido[3',2':4,5]thieno[3,2-d]-N-triazines: a new series of orally active antiallergic agents.
December 1984, Journal of medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Phenolic thiazoles as novel orally-active neuroprotective agents.
January 2004, Bioorganic & medicinal chemistry letters,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection.
June 2001, Journal of medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Novel 2-aminobenzamides as potential orally active antithrombotic agents.
January 2013, ACS medicinal chemistry letters,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Cinnoline-3-propionic acids, a new series of orally active antiallergic substances.
October 1976, Journal of medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and T R Bailey, and P M Carabateas, and E R Bacon, and D C Young, and M G Woods
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.
January 1999, Journal of medicinal chemistry,
Copied contents to your clipboard!